Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN
Browse
PeptideMethods · Tirzepatide · https://peptidemethods.com/peptides/tirzepatide · printed 2026-06-03
GLP-1 / GIP dual agonist

Tirzepatide

Prescription31 resources13 min read · evidence-led · not medical advice
Evidence depth84/100
Source recency90% <3yr
Safety clarity80/100
How we score these
Last updated: 2026-05-30

Reported benefits and downsides

Each item is tagged with the kind of evidence behind it and a strength dial. Read the dial first, the claim second. How we grade evidence strength.

Reported benefits

  • Largest mean weight loss of any approved obesity medicine to dateRCT
    Strong evidence

    SURMOUNT-1 (2022): mean 20.9% body-weight reduction at 72 weeks on 15 mg weekly versus 3.1% on placebo, in adults with obesity but without diabetes.

  • Head-to-head superiority over semaglutide 2.4 mg in obesityRCT
    Strong evidence

    SURMOUNT-5 (Aronne, NEJM 2025): 20.2% mean weight reduction on tirzepatide versus 13.7% on semaglutide at 72 weeks, a 6.5-percentage-point absolute difference (P<0.001).

  • High-efficacy glycaemic control in type-2 diabetesRCT
    Strong evidence

    SURPASS-2 (NEJM 2021): mean HbA1c reductions of 2.01% to 2.30% across the tirzepatide doses versus 1.86% on semaglutide 1 mg.

  • Symptom and event benefit in HFpEF with obesityRCT
    Strong evidence

    SUMMIT (Packer et al., NEJM 2025): hazard ratio 0.62 (95% CI 0.41 to 0.95, P=0.026) for cardiovascular death or worsening heart-failure events, plus a 6.9-point KCCQ-CSS gain over placebo.

  • Reduction in apnea-hypopnea index in obstructive sleep apneaRCT
    Strong evidence

    SURMOUNT-OSA (NEJM 2024): AHI reductions of 25 to 29 events per hour versus 5 on placebo over 52 weeks; basis for the December 2024 FDA Zepbound OSA expansion.

Reported downsides

  • Gastrointestinal side effectsCommon AE
    Strong evidence

    Nausea, diarrhoea, vomiting and constipation are the most common AEs across the trial programme. Dose-dependent and largely mitigated by slow titration but the most common reason people stop.

  • Weight regain after discontinuationEstablished
    Strong evidence

    SURMOUNT-4 (JAMA 2024): the placebo arm regained 14.0% of body weight between week 36 and week 88, while the continued-tirzepatide arm lost a further 5.5%.

  • Thyroid C-cell tumour boxed warningBoxed warning
    Moderate evidence

    Rat data drove the US boxed warning. Human relevance is not determined, but personal or family history of medullary thyroid carcinoma or MEN-2 is a contraindication.

  • Pancreatitis and gallbladder eventsRare AE
    Moderate evidence

    Acute pancreatitis is rare but listed on the label. Gallbladder events (cholelithiasis, cholecystitis) are more common with rapid weight loss.

  • Cost and accessPractical
    Strong evidence

    Branded Mounjaro and Zepbound are expensive; reimbursement varies by country and indication, and NICE TA1026 places the obesity indication inside specific NHS pathways rather than open prescribing.

Where it works, where it doesn't

Where it works

  • Type-2 diabetes that is not adequately controlled by metformin and lifestyle alone (SURPASS programme)
  • Chronic weight management at BMI 30 or higher, or 27 with weight-related comorbidities (Zepbound labelling; SURMOUNT-1, -2, -3)
  • Moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound, FDA expansion December 2024; SURMOUNT-OSA)
  • Obesity-related heart failure with preserved ejection fraction (SUMMIT, NEJM 2025)
  • Patients who can tolerate slow dose-titration through the early GI side-effect window

Where it doesn't

  • Personal or family history of medullary thyroid carcinoma or MEN-2 syndrome (boxed-warning contraindication)
  • Pregnancy and pregnancy-planning windows (contraindicated)
  • Goals built around a defined stop date (SURMOUNT-4 showed substantial weight regain after discontinuation)
  • Type-1 diabetes (not studied; tirzepatide is not insulin-replacement therapy)
  • Cost-sensitive scenarios without insurance coverage; branded Mounjaro and Zepbound remain expensive

Where the literature comes from

An editorial estimate of the kinds of evidence available for Tirzepatide, not just what this page cites. Peptide research is rarely RCT-heavy, so the mix matters as much as the volume.

  • Human RCTs68%
  • Regulatory / agency18%
  • Mechanism / pharmacology8%
  • Systematic reviews4%
  • Case reports / off-label2%

How we estimate this mix: see methodology.

History at a glance

Key moments in the Tirzepatide story, from first synthesis through today.

  1. 2018

    First-in-human phase-1 data published

    Discovery

    Coskun and colleagues describe LY3298176 (tirzepatide), a dual GIP/GLP-1 receptor agonist designed to combine the metabolic actions of both incretins in a single molecule.

  2. 2021

    SURPASS-1 and SURPASS-2 published

    Trial

    Rosenstock et al. (Lancet) report monotherapy efficacy in T2D; Frias et al. (NEJM) report head-to-head superiority over semaglutide 1 mg on HbA1c and weight.

  3. 2022

    FDA approval of Mounjaro for type-2 diabetes

    Approval

    First-in-class dual GIP/GLP-1 receptor agonist authorised in the US (May 2022); weekly subcutaneous dosing.

  4. 2022

    EMA approval of Mounjaro

    Approval

    Centrally authorised across the EU and EEA (September 2022) for type-2 diabetes, with the weight-management indication added subsequently. ATC code A10BX16; MAH Eli Lilly Nederland.

  5. 2022

    SURMOUNT-1 published

    Trial

    Jastreboff et al. (NEJM): mean 20.9% body-weight reduction at 72 weeks on 15 mg weekly versus 3.1% on placebo, in obesity without diabetes.

  6. 2023

    FDA approval of Zepbound for chronic weight management

    Approval

    Tirzepatide authorised in the US under the Zepbound brand for chronic weight management (November 2023), on the SURMOUNT programme data.

  7. 2023

    NICE TA924: tirzepatide for type-2 diabetes

    Regulatory

    NHS England recommends tirzepatide for type-2 diabetes within specified patient pathways (October 2023).

  8. 2024

    SURMOUNT-4 published; FDA expands Zepbound to obstructive sleep apnea

    Approval

    Aronne et al. (JAMA) document weight regain on placebo after week-36 discontinuation; FDA approves Zepbound for OSA in adults with obesity (December 2024) on SURMOUNT-OSA data.

  9. 2024

    NICE TA1026: tirzepatide for managing obesity

    Regulatory

    NHS England recommends tirzepatide for managing overweight and obesity within specified specialist weight-management pathways (December 2024).

  10. 2025

    SUMMIT and SURMOUNT-5 published

    Trial

    Packer et al. (NEJM) report a 38% reduction in CV death or worsening HF in HFpEF plus obesity; Aronne et al. (NEJM) report a 6.5-percentage-point head-to-head advantage over semaglutide 2.4 mg in obesity.

What we know

Tirzepatide is the first dual GIP and GLP-1 receptor agonist to reach a major regulator, and within four years of its first approval it has accumulated one of the heaviest phase-3 trial programmes of any modern peptide. Eli Lilly markets it as Mounjaro for type-2 diabetes (FDA approval May 2022, EMA approval September 2022) and as Zepbound for chronic weight management (FDA approval November 2023) and, more recently, for moderate-to-severe obstructive sleep apnea in adults with obesity (FDA approval December 2024). In the UK, the MHRA licensed Mounjaro for both type-2 diabetes and weight management; NICE published technology appraisal TA924 for the diabetes indication in October 2023 and TA1026 for the weight-management indication in December 2024.

In type-2 diabetes, the SURPASS programme established tirzepatide as a high-efficacy add-on. SURPASS-1 (Rosenstock et al., Lancet 2021) tested tirzepatide monotherapy in adults inadequately controlled on diet and exercise and reported a mean HbA1c reduction of 1.87 percentage points at 40 weeks. SURPASS-2 (Frias et al., NEJM 2021) ran the head-to-head against semaglutide 1 mg in patients on metformin and found tirzepatide superior on both HbA1c (-2.30% at 15 mg vs -1.86% on semaglutide) and weight (a 5.5 kg additional reduction on 15 mg). Across SURPASS-3 through -5 the picture held against insulin degludec, insulin glargine, and across multiple patient populations.

In obesity, the SURMOUNT programme produced what are, at the time of writing, the largest mean weight-loss numbers seen for any approved medicine. SURMOUNT-1 (Jastreboff et al., NEJM 2022) randomised 2,539 adults with obesity but without diabetes to tirzepatide 5, 10 or 15 mg weekly or placebo, all on top of lifestyle intervention. At 72 weeks the mean body-weight reductions were 15.0%, 19.5% and 20.9% versus 3.1% on placebo, and between 50 and 57% of participants on the higher doses reached at least 20% weight loss versus 3% on placebo. SURMOUNT-2 (Garvey et al., Lancet 2023) repeated the trial in adults who also had type-2 diabetes and reported smaller but still substantial losses of 12.8% and 14.7% on 10 and 15 mg versus 3.2% on placebo. SURMOUNT-3 (Wadden et al., Nat Med 2023) tested tirzepatide added after a 12-week intensive lifestyle intervention.

SURMOUNT-4 (Aronne et al., JAMA 2024) is the discontinuation study and the one to know about. Participants spent 36 open-label weeks on maximum tolerated tirzepatide (10 or 15 mg), losing a mean 20.9% of baseline body weight, then were randomised either to continue tirzepatide or to switch to placebo for another 52 weeks. From week 36 to week 88, the continued-tirzepatide arm lost a further 5.5% on average, while the placebo arm regained 14.0%. By week 88 the cumulative loss was 25.3% on continued tirzepatide and 9.9% on placebo. The message that drove most 2024 to 2026 clinical practice is that this is a chronic therapy: stop the drug, get most of the weight back.

SURMOUNT-5 (Aronne et al., NEJM 2025) is the head-to-head trial readers most often ask about. Seven hundred and fifty-one adults with obesity but without diabetes were randomised to maximum tolerated tirzepatide (10 or 15 mg) or to maximum tolerated semaglutide 2.4 mg (Wegovy) for 72 weeks. Tirzepatide produced a mean body-weight reduction of 20.2% versus 13.7% on semaglutide, an absolute difference of 6.5 percentage points (P<0.001). Waist-circumference reduction favoured tirzepatide by a similar margin. The adverse-event profile, as in the rest of the programme, was dominated by gastrointestinal events that were largely mild to moderate and concentrated in the dose-escalation period. SURMOUNT-OSA (Malhotra et al., NEJM 2024) ran the same molecule against placebo in 469 adults with moderate-to-severe obstructive sleep apnea and obesity and reported AHI (apnea-hypopnea index) reductions of 25 to 29 events per hour versus 5 on placebo, which is what drove the December 2024 FDA Zepbound expansion to the OSA indication.

Cardiovascular-outcomes evidence is emerging. SUMMIT (Packer et al., NEJM 2025) randomised 731 adults with obesity-related heart failure with preserved ejection fraction (HFpEF) to tirzepatide or placebo for a median 104 weeks and reported a 38% reduction in the composite of cardiovascular death or worsening heart-failure events (hazard ratio 0.62, 95% CI 0.41 to 0.95, P=0.026) alongside meaningful improvements in symptom burden on the Kansas City Cardiomyopathy Questionnaire (+19.5 vs +12.7, a between-group difference of 6.9 points). A dedicated MACE outcomes trial in the obesity-without-diabetes population, matching what SELECT did for semaglutide, has not yet read out at the time of writing.

In the EU and EEA, Mounjaro is centrally authorised through the EMA for both type-2 diabetes and weight management (Eli Lilly Nederland is the marketing authorisation holder; ATC code A10BX16). In the UK, the MHRA licenses Mounjaro for the same two indications, with NICE technology appraisals TA924 (T2D, 2023) and TA1026 (obesity, 2024) shaping NHS access. In the US, Mounjaro is approved for type-2 diabetes and Zepbound, the same molecule under a different brand at the same dose range, is approved for chronic weight management and for obstructive sleep apnea in adults with obesity. All presentations are prescription-only across our coverage area; none is sold over the counter anywhere.

A note on supply. Tirzepatide spent a period on the FDA drug-shortage list in 2022 and 2023, during which US compounding pharmacies could legally prepare versions of it under sections 503A and 503B of the FD&C Act. The FDA has since declared the shortage resolved, and large-scale compounding of tirzepatide is no longer permitted under enforcement discretion. The branded products (Mounjaro and Zepbound) are the authorised route. Parallel grey-market 'research-use only' vials of tirzepatide circulate online; that label does not legalise human use, does not guarantee pharmaceutical-grade purity, and does not put the product inside any of the regulatory frameworks (EMA, MHRA, FDA) the branded versions operate under. PeptideMethods covers this honestly but does not facilitate the sale of any peptide.

This page is for educational and journalistic purposes. We do not advise on starting, stopping, dosing, or sourcing tirzepatide. Those conversations belong with a clinician who knows your history. Use the country pages below to see how tirzepatide is regulated where you live, the FAQ to surface the most-asked questions, and the source list to read the primary trial and regulatory documents in full.

How it works

Tirzepatide is a 39-amino-acid synthetic peptide modified with a C20 fatty diacid (a 20-carbon fatty chain), attached via a gamma-glutamic-acid linker and two AEEA spacers (short polyethylene-glycol-like chemistry that lengthens the chain and protects against rapid enzymatic breakdown). The molecule acts as a dual agonist: it binds and activates both the GIP receptor (the receptor for glucose-dependent insulinotropic polypeptide, a gut hormone released after eating that primarily amplifies insulin release when blood glucose is high) and the GLP-1 receptor (the receptor for glucagon-like peptide-1, the gut hormone that drives insulin release and signals fullness to the brain). The lipidation makes the drug cling reversibly to albumin in the blood (the most abundant blood protein, which slows clearance), stretching the elimination half-life to about five days and enabling once-weekly subcutaneous dosing. Three pharmacological effects matter clinically: enhanced glucose-dependent insulin secretion (insulin is released only when blood glucose is already elevated, so the hypoglycaemia risk on monotherapy is low), suppression of glucagon (the hormone that raises blood sugar by telling the liver to release stored glucose), and slowed gastric emptying (food leaves the stomach more slowly, prolonging fullness). The weight-loss effect is driven primarily centrally, through GIP and GLP-1 receptors in the hypothalamus and brainstem (the brain regions that regulate appetite and satiety). Whether the GIP arm adds a muscle-sparing or fat-targeting effect on top of GLP-1 alone is still being characterised; the head-to-head SURMOUNT-5 data say the combined molecule loses more total weight than semaglutide, but the long-term body-composition story is not fully settled.

Where it acts in the body

  1. Hypothalamus and brainstemActivates central GIP and GLP-1 receptors to suppress appetite and prolong satiety. The dominant driver of weight loss.
  2. PancreasEnhances glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose without driving hypoglycaemia on its own.
  3. StomachSlows gastric emptying, prolonging the feeling of fullness after meals and contributing to GI side effects.
  4. Adipose tissueGIP receptors are expressed on adipocytes; the GIP arm is hypothesised to contribute to lipid handling and energy expenditure, though the human-clinical contribution beyond GLP-1 alone is still being characterised.
  5. Cardiovascular systemSUMMIT (NEJM 2025) reports reduced cardiovascular death and worsening heart-failure events in HFpEF with obesity over a median 104 weeks.
  6. Upper airway / respiratory driveSURMOUNT-OSA (NEJM 2024) reports large reductions in apnea-hypopnea index in adults with obesity and obstructive sleep apnea, partly weight-mediated.

Safety

The dominant adverse-event signal across the SURPASS (diabetes) and SURMOUNT (weight) programmes is gastrointestinal: nausea, diarrhoea, vomiting and constipation, all dose-dependent and largely mitigated by slow titration. In SURMOUNT-1, treatment discontinuation for adverse events ran 4.3% to 7.1% across the tirzepatide groups versus 2.6% on placebo. Less common but clinically meaningful events include acute pancreatitis, gallbladder events (cholelithiasis, cholecystitis) which are more common with rapid weight loss, and acute kidney injury secondary to dehydration. The US Mounjaro label carries a boxed warning: tirzepatide causes thyroid C-cell tumours in rats, and the human relevance has not been determined. Personal or family history of medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN-2) are contraindications. Hypoglycaemia risk is low on monotherapy but rises when tirzepatide is combined with insulin or a sulfonylurea. Pregnancy is a contraindication, and the EMA SmPC notes the possibility of reduced efficacy of oral hormonal contraceptives during dose escalation. Diabetic retinopathy progression is on the EU SmPC list of identified risks, consistent with the broader GLP-1 class signal.

Practical considerations

How the literature has dosed Tirzepatide, what it costs where it's authorised, how to spot a counterfeit product, and the customs reality. We report. We do not prescribe.

Dosing & administration

Once-weekly subcutaneous injection, available in 2.5, 5, 7.5, 10, 12.5 and 15 mg pen strengths. The label starts at 2.5 mg for the first four weeks (a non-therapeutic starting dose intended to reduce GI side effects), then escalates in 2.5 mg increments every four weeks as tolerated. Approved doses depend on indication and are in each product's label.

ContextRangeReference
SURPASS programme (type-2 diabetes)5, 10 or 15 mg weekly subcutaneously, after a 2.5 mg starting doseSURPASS-1 (Rosenstock 2021) and the broader SURPASS-1 through -5 series
SURMOUNT-1 (chronic weight management)Titrated to 5, 10 or 15 mg weekly subcutaneously over 20 weeksJastreboff et al., NEJM 2022
SURMOUNT-4 (maintenance)Maximum tolerated dose 10 or 15 mg weekly for the open-label lead-in; randomised continuation versus placebo at week 36Aronne et al., JAMA 2024
SURMOUNT-5 (head-to-head vs semaglutide)Maximum tolerated tirzepatide 10 or 15 mg weekly vs maximum tolerated semaglutide 1.7 or 2.4 mg weeklyAronne et al., NEJM 2025
SURMOUNT-OSA (obstructive sleep apnea)Maximum tolerated 10 or 15 mg weekly over 52 weeksMalhotra et al., NEJM 2024

All trial dosing was clinician-supervised with structured titration to manage gastrointestinal side effects. Real-world starting and target doses depend on indication, weight, comorbidities and tolerability. We report what the literature used. We do not recommend a dose. That conversation belongs with a prescribing clinician.

Cost & access

Branded Mounjaro and Zepbound pens are expensive and reimbursement varies sharply by country and by indication. Figures below are approximate 2026 ballparks; verify with the regulator, the manufacturer's patient-assistance programme, or your local pharmacy.

United States
Mounjaro and Zepbound list cash prices commonly cited in the $1,000 to $1,300 monthly range. Eli Lilly's LillyDirect and patient-assistance programmes may reduce the price for eligible patients. Insurance coverage depends on indication (T2D coverage broader than obesity or OSA) and plan.
United Kingdom
Available on the NHS within NICE TA924 (T2D) and TA1026 (obesity) criteria, with phased implementation across specialist weight-management services. Private prescription pricing varies by dose and pharmacy.
Denmark, Sweden, Norway
Reimbursed for type-2 diabetes within national criteria. Obesity-indication reimbursement is more restrictive and may require specialist referral.
Germany, Netherlands
Type-2 diabetes is reimbursed under standard criteria. Obesity-indication coverage is patchier and often paid out-of-pocket.

Travel & customs

Holders of a valid prescription for Mounjaro or Zepbound can generally travel with the medication across our coverage area. Carry the original packaging, a copy of the prescription, and a doctor's letter if travelling outside Europe. Customs may detain unverified or compounded versions, and personal importation of unapproved versions is generally not permitted.

In the conversation

Credentialed experts and podcasters who have covered Tirzepatide on the record. We link the original source, attribute by full name, and disclose any conflict of interest. We do not paraphrase as if it were our work.

  1. Casey H. Halpern, MD; Kelly Allison, PhD; Wonkyung Choi (Penn Medicine)Tier 2ArticlePenn Medicine News: Tirzepatide may only temporarily suppress brain activity involved in 'food noise'Nov 2025

    Penn Medicine reports a Nature Medicine case study using direct intracranial recordings from the nucleus accumbens of a patient on tirzepatide. Halpern: 'This study offers major insights into how these drugs may work inside the brain and will guide us as we explore new indications.' He warns directly against overreach: 'Until we better understand their action on the brain, it's far too soon to call GLP-1 and GIP inhibitors miracle drugs for more conditions beyond type 2 diabetes and obesity.' Allison adds that the drugs are 'amazing medications at doing what they were developed for' but the recordings suggest the food-craving suppression may not be durable. Tirzepatide silenced nucleus-accumbens activity early, then activity returned at 5 months alongside renewed food preoccupation.

    Conflict of interest: Halpern's lab researches deep-brain stimulation for obesity (competing intervention); funding sources include NIH and device-industry partners.

    Read→

  2. Spencer Nadolsky, DOTier 2PodcastSigma Nutrition Radio #582 (host Danny Lennon): GLP-1 Agonists, Side Effects, Management and DietOct 2025

    Episode chaptered into mechanism (5:24), efficacy (7:55), side effects (16:53), muscle loss (22:57) and accessibility (36:59). Nadolsky frames the class in plain terms: 'Tirzepatide is a dual agonist that activates both GLP-1 and GIP receptors (hence nicknamed a twincretin).' The host-curated summary positions GLP-1 agonists as the largest pharmacological shift in obesity care since bariatric surgery and works through nausea, vomiting, and lean-mass concerns that come with rapid weight loss.

    Conflict of interest: Nadolsky operates a virtual obesity-medicine clinic that prescribes GLP-1 drugs including tirzepatide; previously chief medical officer at WeightWatchers.

    Listen→ at 00:05:24

  3. Peter Attia, MDTier 3NewsletterPeter Attia, MD: Research Worth Sharing, July 2025Jul 2025

    Attia's July round-up frames the class plainly: 'GLP-1 receptor agonist drugs (GLP1-RAs) like semaglutide (trade names Ozempic, Wegovy) and tirzepatide (trade names Mounjaro, Zepbound) have proven to be game-changers.' The post walks through a trial where 'both groups were given equivalent doses of tirzepatide for weight loss throughout the trial', positioning tirzepatide as the active comparator backbone in research aimed at preserving lean mass. The piece is light commentary rather than a primary-source-cited segment, so we mark it Tier 3.

    Conflict of interest: Operates Early Medical, a longevity clinic with a GLP-1 prescribing line; Momentous supplement-line affiliation; active book and podcast businesses.

    Read→

  4. Karl Nadolsky, MD; Spencer Nadolsky, DOTier 3PodcastDocs Who Lift Podcast: Zepbound versus Wegovy (SURMOUNT-5 full data and cost-effectiveness)May 2025

    Episode published the day after SURMOUNT-5 was published in NEJM. Show notes summarise the takeaway in two lines: 'Tirzepatide is more effective for weight loss than semaglutide' and 'Cost-effectiveness is crucial in prescribing weight loss medications.' The hosts also note that 'Future studies are needed to confirm cardiovascular benefits of tirzepatide', an honest read consistent with the absence of a dedicated tirzepatide MACE-outcomes trial in obesity without diabetes at the time of recording. Available show-notes text is limited, so we mark this Tier 3.

    Conflict of interest: Karl Nadolsky chairs the AACE Obesity Task Force; Spencer Nadolsky runs a virtual GLP-1 prescribing clinic and was previously CMO at WeightWatchers.

    Listen→

  5. Karl Nadolsky, MD; Spencer Nadolsky, DOTier 2PodcastDocs Who Lift Podcast: Zepbound vs Wegovy trial and compounded GLP-1s (SURMOUNT-5 topline; FDA compounding update)Dec 2024

    Show notes verbatim: 'Drs. Karl and Spencer discuss the topline results from Surmount 5 which put Zepbound (tirzepatide) against Wegovy (semaglutide) for weight loss.' Three learning objectives stated on the page: 'Weight loss and glycemic differences between tirzepatide and semaglutide; What the FDA is thinking for compounded GLP-1s; Information about Dr. Spencer's virtual clinic waitlist.' Recorded five days after Eli Lilly's December 4 2024 topline press release and three weeks before the FDA's December 19 declaratory order resolving the tirzepatide shortage.

    Conflict of interest: Karl Nadolsky chairs the AACE Obesity Task Force; Spencer Nadolsky runs a virtual GLP-1 prescribing clinic. The episode itself promotes Spencer's clinic waitlist.

    Listen→

  6. Milton Packer, MD; Robert Mentz, MD; Sanjiv Shah, MD; Jennifer Ho, MDTier 2ArticleTCTMD (M. O'Riordan): SUMMIT, Tirzepatide a Huge Win for HFpEF Patients With ObesityNov 2024

    Coverage of the AHA 2024 SUMMIT presentation that landed simultaneously in NEJM (Packer et al.). Shah (Northwestern): 'With SUMMIT, I think we really feel comfortable saying that these drugs are here to stay for HFpEF.' Mentz (Duke): 'Now, these data are really building this case that there's clinical outcome benefit.' Ho (Beth Israel Deaconess): 'This is going to affect how we think about the majority of patients with HFpEF.' Shah on patient impact: 'For our patients, this is a huge win.' The piece grounds the 38% reduction in the composite of cardiovascular death or worsening heart failure in the broader question of whether tirzepatide's effect is driven by weight loss alone or by direct cardiac and anti-inflammatory mechanisms, an open question the SUMMIT CMR substudy and secondary analyses are now examining.

    Conflict of interest: Packer led the trial and discloses consulting for Lilly. Mentz, Shah and Ho all receive academic-pharma research support consistent with leading HF clinical trialists.

    Read→

  7. Eric Topol, MDTier 2NewsletterEric Topol, Ground Truths: Daniel Drucker, Illuminating the GLP-1 Drug's Break OutApr 2024

    Long-form interview with Daniel Drucker, one of the co-discoverers of GLP-1 biology. On efficacy: 'tirzepatide from Lilly, that's spectacular, that's producing more than 20% weight loss.' On durability, paraphrasing SURMOUNT-4-style data: 'more than 40% of the people still managed to keep at least 10% of their weight off, which is more than enough in many people to bestow considerable metabolic health.' On the chronic-treatment framing: 'when we're excited about heart attacks and strokes and chronic kidney disease, there's no evidence that you can stop the medicines and still get the benefits to reduce those chronic complications.' Strong primary-discipline source pointing at the same SURMOUNT-4 picture we describe in the page body: the drug works as a chronic therapy, not a course.

    Conflict of interest: Scripps Research; publishes books and the Ground Truths newsletter. No direct GLP-1 commercial interest disclosed.

    Read→

  8. Eric Topol, MDTier 2NewsletterEric Topol, Ground Truths: The New Obesity Breakthrough DrugsDec 2022

    Topol's first Ground Truths essay on the class, published six months after FDA approval of Mounjaro. On efficacy: 'Tirzepatide at dose of 10 to 15 mg per week achieved more than 20% body weight reduction.' On mechanism: 'tirzepatide is in a new class of dual agonists: it activates (mimics) both the GLP-1 receptor and GIP receptors.' On the head-to-head SURPASS-2 result that anticipated SURMOUNT-5: 'tirzepatide was superior to semaglutide.' On pipeline status at the time: 'The next drug on fast track at FDA to be imminently approved is tirzepatide (Mounjaro).' Useful as the early framing of the dual-agonist story, written ahead of the Zepbound approval.

    Conflict of interest: Scripps Research, cardiologist; no direct GLP-1 commercial interest disclosed.

    Read→

Vetted vendors

Vendor reviews launching Q3 2026

We order from vendors ourselves, send samples to an independent lab, and publish what we find, including the ones that get it wrong. Tirzepatide-specific vendor reviews will live here when the testing programme is live. Until then, please assume any online seller is unverified.

Latest updates

  1. 11 Dec 2025

    EMA CHMP positive opinion to extend Mounjaro to paediatric and adolescent type-2 diabetes (10+)

    CHMP recommended extending Mounjaro's licensed indication to adolescents and children aged 10 and over with insufficiently controlled type-2 diabetes, on the SURPASS-PEDS programme data. The updated indication will read: 'Mounjaro is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus.' MAH: Eli Lilly Nederland B.V.

  2. 17 Nov 2025

    Penn Medicine / Nature Medicine: tirzepatide may only temporarily quiet 'food noise'

    A Nature Medicine case report by Casey Halpern and colleagues used implanted intracranial electrodes to record nucleus-accumbens activity in a single patient on tirzepatide. NAc activity was suppressed early in treatment alongside resolved food preoccupation, then re-emerged at five months with renewed cravings. Halpern: 'Until we better understand their action on the brain, it's far too soon to call GLP-1 and GIP inhibitors miracle drugs for more conditions beyond type 2 diabetes and obesity.'

  3. 2 Sept 2025

    Post-hoc SURMOUNT-5: tirzepatide cuts predicted 10-year CVD risk more than semaglutide

    Mamas et al. (European Heart Journal Open) report a post-hoc analysis of SURMOUNT-5. Treatment with tirzepatide was associated with a significantly greater absolute reduction in predicted 10-year CVD risk than semaglutide (-2.4% vs -1.4%, P<0.001). Scaled to the eligible US population, the authors project around 2 million CVD events potentially preventable over 10 years with tirzepatide versus 1.15 million with semaglutide.

  4. 11 May 2025

    SURMOUNT-5 published: tirzepatide beats semaglutide head-to-head

    Aronne et al. (NEJM) report a 20.2% mean weight reduction on tirzepatide versus 13.7% on semaglutide 2.4 mg at 72 weeks in 751 adults with obesity but without diabetes, a 6.5-percentage-point absolute difference (P<0.001). First adequately powered head-to-head obesity comparison in the modern GLP-1 era.

  5. 20 Dec 2024

    FDA approves Zepbound for obstructive sleep apnea

    Tirzepatide becomes the first medicine approved in the US for moderate-to-severe OSA in adults with obesity, on the SURMOUNT-OSA data (Malhotra et al., NEJM 2024).

  6. 16 Nov 2024

    SUMMIT: tirzepatide reduces CV death and worsening HF in HFpEF plus obesity

    Packer et al. (NEJM) report a 38% reduction in the composite of cardiovascular death or worsening heart-failure events (HR 0.62, P=0.026) in 731 adults with HFpEF and obesity over a median 104 weeks.

Frequently asked

Is tirzepatide more effective than semaglutide?

On the head-to-head numbers, yes, for weight loss in obesity without diabetes. SURMOUNT-5 (Aronne et al., NEJM 2025) randomised 751 adults to maximum tolerated tirzepatide (10 or 15 mg) versus maximum tolerated semaglutide 2.4 mg for 72 weeks and reported a mean weight reduction of 20.2% on tirzepatide versus 13.7% on semaglutide, a 6.5-percentage-point absolute difference (P<0.001). For type-2 diabetes glycaemic control, SURPASS-2 (Frias et al., NEJM 2021) had already shown tirzepatide superior to semaglutide 1 mg on HbA1c reduction. What the head-to-heads do not yet settle: long-term cardiovascular outcomes in obesity without diabetes (SELECT exists for semaglutide; an equivalent dedicated MACE trial for tirzepatide has not yet read out).

What is the difference between Mounjaro and Zepbound?

They are the same molecule, tirzepatide, sold under different brand names for different indications. Mounjaro is approved in the US, EU, EEA and UK for type-2 diabetes (and in the EU and UK additionally for weight management). Zepbound is the US brand for chronic weight management (approved November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (approved December 2024). The pens come in the same 2.5, 5, 7.5, 10, 12.5 and 15 mg dose strengths.

What happens when you stop tirzepatide?

SURMOUNT-4 (Aronne et al., JAMA 2024) is the discontinuation trial. Participants spent 36 weeks on maximum tolerated tirzepatide losing a mean 20.9% of body weight, then were randomised to continue or switch to placebo. From week 36 to 88, the placebo arm regained 14.0% on average while the continued-tirzepatide arm lost a further 5.5%. Most of the early loss came back when the drug was stopped. The practical implication is that tirzepatide treats obesity as a chronic disease, not as a course of treatment with a defined end.

Is tirzepatide safe?

It has been studied in tens of thousands of patients across the SURPASS, SURMOUNT, SURMOUNT-OSA and SUMMIT programmes and has a reasonably well-characterised short-to-medium-term adverse-event profile: predominantly gastrointestinal (nausea, diarrhoea, vomiting, constipation), with smaller signals for pancreatitis, gallbladder events, and acute kidney injury secondary to dehydration. The US label carries a boxed warning that tirzepatide causes thyroid C-cell tumours in rats, with human relevance not determined; personal or family history of medullary thyroid carcinoma and MEN-2 are contraindications. Long-horizon safety in years-to-decades chronic dosing in obesity is still accumulating. As with any prescription medicine, safety depends on individual context. That conversation belongs with a clinician.

Can I buy 'research grade' tirzepatide online?

Vials labelled 'tirzepatide, for research use only' exist on the grey market. That label does not legalise human use, does not guarantee pharmaceutical-grade purity, and does not put the product inside any of the regulatory frameworks (EMA, MHRA, FDA) that the branded products operate under. Regulators across our coverage area treat these as unauthorised medicines. Independent testing of grey-market peptides as a category finds frequent purity, identity and contamination failures. PeptideMethods does not facilitate the sale of any peptide and does not endorse this route.

Is tirzepatide approved for cardiovascular-event reduction?

Not yet in obesity without diabetes, and not as a standalone MACE-reduction indication on the label. The strongest CV-outcomes evidence so far is SUMMIT (Packer et al., NEJM 2025), in adults with obesity-related heart failure with preserved ejection fraction, which reported a 38% reduction in the composite of cardiovascular death or worsening heart-failure events (HR 0.62, P=0.026). The dedicated MACE outcomes trial in obesity without diabetes that would match what SELECT did for semaglutide has not yet read out at the time of writing.

Primary sources
  1. Shukla et al. (2026): Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight, SURMOUNT-5 (Diabetes Obes Metab; PMID 41187971)Tier 1
  2. Mamas et al. (2025): Tirzepatide vs semaglutide and 10-year cardiovascular disease risk reduction, post-hoc SURMOUNT-5 (European Heart Journal Open; PMID 40980721)Tier 1
  3. Look et al. (2025): Body composition changes during weight reduction with tirzepatide in SURMOUNT-1 (Diabetes Obes Metab; PMID 39996356)Tier 1
  4. Mounjaro (tirzepatide): EMA EPAR (centrally authorised for type-2 diabetes and weight management; ATC A10BX16; MAH Eli Lilly Nederland)Tier 1
  5. Mounjaro (tirzepatide) prescribing information with boxed warning, DailyMed (NLM)Tier 1
  6. Tirzepatide: PubChem compound page (CID 156588324; formula C225H348N48O68; 39-aa modified peptide)Tier 1
  7. NICE TA924: tirzepatide for treating type-2 diabetes (published 25 October 2023)Tier 1
  8. NICE TA1026: tirzepatide for managing overweight and obesity (published 23 December 2024)Tier 1
  9. SURMOUNT-1: Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022; PMID 35658024)Tier 1
  10. SURMOUNT-2: Garvey et al., Tirzepatide once weekly for obesity in people with type-2 diabetes (Lancet, 2023; PMID 37385275)Tier 1
  11. SURMOUNT-3: Wadden et al., Tirzepatide after intensive lifestyle intervention (Nat Med, 2023; PMID 37840095)Tier 1
  12. SURMOUNT-4: Aronne et al., Continued treatment with tirzepatide for maintenance of weight reduction, JAMA 2024 (PMID 38078870)Tier 1
  13. SURMOUNT-5: Aronne et al., Tirzepatide as compared with semaglutide for the treatment of obesity (NEJM, 2025; PMID 40353578)Tier 1
  14. SURMOUNT-OSA: Malhotra et al., Tirzepatide for obstructive sleep apnea and obesity (NEJM, 2024; PMID 38912654)Tier 1
  15. SURPASS-1: Rosenstock et al., Tirzepatide monotherapy versus placebo in T2D (Lancet, 2021; PMID 34186022)Tier 1
  16. SURPASS-2: Frias et al., Tirzepatide versus semaglutide once weekly in patients with type-2 diabetes (NEJM, 2021; PMID 34170647)Tier 1
  17. SUMMIT: Packer et al., Tirzepatide for heart failure with preserved ejection fraction and obesity (NEJM, 2025; PMID 39555826)Tier 1

Glossary

Quick definitions for the technical terms used on this page. Hover any term in the body text and most browsers show the same definition; this section is the canonical reference.

AEEA spacer
Short polyethylene-glycol-like chemistry used to lengthen a peptide chain and protect it from rapid enzymatic breakdown. Two AEEA spacers link tirzepatide's peptide backbone to its fatty diacid tail.
AHI
Apnea-hypopnea index. Number of apnea and hypopnea events per hour of sleep. Primary endpoint in SURMOUNT-OSA.
Dual agonist
A drug that binds and activates two different receptors at clinically meaningful potency. Tirzepatide is a dual GIP and GLP-1 receptor agonist.
GIP
Glucose-dependent insulinotropic polypeptide. A gut hormone released after eating that amplifies insulin release when blood glucose is high. One of the two receptors tirzepatide activates.
GLP-1
Glucagon-like peptide-1. A gut hormone that prompts insulin release and signals fullness to the brain. The other receptor tirzepatide activates.
HbA1c
A blood test reflecting average glucose over the previous 8 to 12 weeks. The standard glycaemic-control marker in diabetes.
HFpEF
Heart failure with preserved ejection fraction. A common form of heart failure in which the heart contracts normally but does not relax and fill properly. Studied in the SUMMIT trial.
MACE
Major adverse cardiovascular events. Composite endpoint typically including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Medullary thyroid carcinoma (MTC)
A rare thyroid cancer arising from parafollicular C cells. A boxed-warning contraindication for tirzepatide.
MEN-2
Multiple endocrine neoplasia type 2. A genetic syndrome that predisposes carriers to medullary thyroid carcinoma. Contraindication for tirzepatide.
RCT
Randomised controlled trial. The standard for evaluating whether a treatment causes a measured effect.
Titration
Gradual dose escalation over weeks. Used with tirzepatide to reduce gastrointestinal side effects.

Recent coverage

All blog posts →

Three most recent articles from the daily editorial pipeline that mention Tirzepatide.

PeptideMethods · This page is educational, not medical advice. Verified 2026-05-30 · © 2026 Digital Compass Group Ltd · peptidemethods.com